Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bacitracin zinc + polymyxin b is a fixed-dose **ophthalmic antibiotic combination** used topically for superficial bacterial infections of the external eye and its adnexa, including conjunctivitis, keratitis, keratoconjunctivitis, blepharitis, and blepharoconjunctivitis caused by susceptible organisms. The product combines bacitracin zinc, a cyclic polypeptide antibiotic that inhibits bacterial cell wall synthesis, with polymyxin b, a polypeptide antibiotic that disrupts bacterial cell membrane integrity, providing complementary Gram-positive and Gram-negative antibacterial coverage. It is marketed as an ophthalmic ointment, including under the brand name Polycin, and has been associated with manufacturers such as Bausch & Lomb, Akorn, and Fougera.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bacitracin zinc + polymyxin b.